| Tumor microenvironment promotes breast cancer chemoresistance U Mehraj, AH Dar, NA Wani, MA Mir Cancer chemotherapy and pharmacology 87 (2), 147-158, 2021 | 181 | 2021 |
| The tumor microenvironment as driver of stemness and therapeutic resistance in breast cancer: New challenges and therapeutic opportunities U Mehraj, RA Ganai, MA Macha, A Hamid, MA Zargar, AA Bhat, ... Cellular Oncology, 1-21, 2021 | 82 | 2021 |
| Targeting Different Pathways Using Novel Combination Therapy in Triple Negative Breast Cancer MA Mir, H Qayoom, U Mehraj, S Nisar, B Bhat, NA Wani Current Cancer Drug Targets 20 (8), 586-602, 2020 | 79 | 2020 |
| Targeting cyclin-dependent kinase 1 (CDK1) in cancer: molecular docking and dynamic simulations of potential CDK1 inhibitors S Sofi, U Mehraj, H Qayoom, S Aisha, A Almilaibary, M Alkhanani, MA Mir Medical Oncology 39 (9), 133, 2022 | 75 | 2022 |
| Cyclin-dependent kinases in breast cancer: expression pattern and therapeutic implications S Sofi, U Mehraj, H Qayoom, S Aisha, SMB Asdaq, A Almilaibary, MA Mir Medical Oncology 39 (6), 106, 2022 | 67 | 2022 |
| Prognostic significance and targeting tumor-associated macrophages in cancer: new insights and future perspectives U Mehraj, H Qayoom, MA Mir Breast Cancer 28 (3), 539-555, 2021 | 63 | 2021 |
| Nanobodies: The “magic bullets” in therapeutics, drug delivery and diagnostics MA Mir, U Mehraj, BA Sheikh, SS Hamdani Human antibodies 28 (1), 29-51, 2020 | 58 | 2020 |
| Expression pattern and prognostic significance of baculoviral inhibitor of apoptosis repeat-containing 5 (BIRC5) in breast cancer: A comprehensive analysis U Mehraj, S Aisha, S Sofi, MA Mir Advances in Cancer Biology-Metastasis, 100037, 2022 | 45 | 2022 |
| Double-crosser of the Immune System: Macrophages in Tumor Progression and Metastasis MA Mir, U Mehraj Current Immunology Reviews 15 (2), 172-184, 2019 | 45 | 2019 |
| Chemokines in triple-negative breast cancer heterogeneity: New challenges for clinical implications U Mehraj, U Mushtaq, MA Mir, A Saleem, MA Macha, MN Lone, A Hamid, ... Seminars in Cancer Biology 86, 769-783, 2022 | 44 | 2022 |
| Development of new therapeutics to meet the current challenge of drug resistant tuberculosis BA Sheikh, BA Bhat, U Mehraj, W Mir, S Hamadani, MA Mir Current Pharmaceutical Biotechnology 22 (4), 480-500, 2021 | 41 | 2021 |
| Expression patterns and therapeutic implications of CDK4 across multiple carcinomas: a molecular docking and MD simulation study H Qayoom, U Mehraj, S Sofi, S Aisha, A Almilaibary, M Alkhanani, MA Mir Medical Oncology 39 (10), 158, 2022 | 32 | 2022 |
| Expression pattern and prognostic significance of chemokines in breast cancer: an integrated bioinformatics analysis U Mehraj, B Alshehri, AA Khan, AA Bhat, P Bagga, NA Wani, MA Mir Clinical Breast Cancer 22 (6), 567-578, 2022 | 29 | 2022 |
| Expression pattern and prognostic significance of CDKs in breast cancer: an integrated bioinformatic study U Mehraj, S Sofi, B Alshehri, MA Mir Cancer Biomarkers 34 (3), 505-519, 2022 | 28 | 2022 |
| Adapalene and doxorubicin synergistically promote apoptosis of TNBC Cells by hyperactivation of the ERK1/2 pathway through ROS induction U Mehraj, IA Mir, M Hussain, M Alkhanani, NA Wani, MA Mir Frontiers in oncology 12, 938052, 2022 | 26 | 2022 |
| Recent Advances in Metabolites from Medicinal Plants in Cancer Prevention and Treatment MA Mir, SS Hamdani, BA Sheikh, U Mehraj Current Immunology Reviews 15 (2), 185-201, 2019 | 25 | 2019 |
| Rising trends of cancers in Kashmir valley: distribution pattern, incidence and causes H Qayoom, BA Bhat, U Mehraj, MA Mir J Oncol Res Treat 5 (150), 2, 2020 | 23 | 2020 |
| Cryptolepine targets TOP2A and inhibits tumor cell proliferation in breast cancer cells-an in vitro and in silico study U Mehraj, H Qayoom, S Shafi, P Farhana, S Asdaq, MA Mir Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal …, 2022 | 22 | 2022 |
| Adapalene inhibits the growth of triple-negative breast cancer cells by S-phase arrest and potentiates the antitumor efficacy of GDC-0941 U Mehraj, NA Wani, A Hamid, M Alkhanani, A Almilaibary, MA Mir Frontiers in pharmacology 13, 958443, 2022 | 21 | 2022 |
| Recent advances in chemotherapeutic implications of deguelin: a plant-derived retinoid MA Mir, U Mehraj, BA Sheikh The Natural Products Journal 11 (2), 169-181, 2021 | 17 | 2021 |
Dr Manzoor Ahmad MirUniversity of Kashmir在 kashmiruniversity.ac.in 的电子邮件经过验证
